Earnings call transcript: BICO Group Q2 2025 revenue drops, stock plunges

BICO Group reported a challenging Q2 2025, with revenue of $324 million significantly missing forecasts and organic growth declining 17%, leading to a $49 million adjusted EBITDA loss. This performance, attributed to macroeconomic uncertainties, a soft academic market, and operational inefficiencies including project delays in its lab automation division, triggered a 22.38% stock price decline. Despite the setbacks, BICO has bolstered its cash reserves to $1.4 billion through strategic divestments and is implementing comprehensive operational improvements while shifting its market focus towards pharma and biotech, anticipating a stronger second half as these changes take effect.

Analysis

BICO Group reported a significantly challenging second quarter for 2025, with revenue of $324 million falling well short of the $430.73 million forecast, driven by a 17% decline in organic growth. This top-line miss translated into a substantial adjusted EBITDA loss of $49 million, representing a negative 15% margin. The poor performance was primarily attributed to severe operational issues within the Lab Automation business area, which saw a 58% sales decline stemming from project delays and a negative revenue impact of approximately SEK 40 million due to the re-estimation of project hours. The market reacted sharply, with the company's stock plunging 22.38%, reflecting deep investor concern over execution capabilities.

Despite these operational failures, the company has undertaken significant strategic repositioning. The divestment of non-core assets Mattek and Visicol has fortified the balance sheet, boosting cash reserves to $1.4 billion and creating a net cash position. Management is now implementing a comprehensive turnaround plan for the Lab Automation unit, involving leadership changes and new process controls to address project management deficiencies. Concurrently, BICO is pivoting its commercial focus from the soft, NIH funding-constrained academic market towards the pharma and biotech sectors. While management expects a stronger second half without the one-off project-related charges, external analyst forecasts project an 18% revenue decline for the full year, highlighting the significant execution risk that remains. The stock's Price-to-Book ratio of 0.94 suggests it is trading below its book value, presenting a potential value opportunity if the turnaround strategy proves successful.

Key Decisions for Investors

• Investors should closely monitor the execution of the turnaround plan in the Lab Automation (BioSero) division, as its ability to stabilize project delivery and improve margins is the primary catalyst for a potential recovery.
• The strengthened balance sheet, with $1.4 billion in cash, provides a crucial buffer to fund the operational overhaul, but progress in the shift away from the challenged academic market towards pharma and biotech clients must be scrutinized for evidence of sustainable growth.
• Given the stock is trading below book value (P/B of 0.94) amid significant operational distress, this represents a high-risk turnaround situation; potential investors should await tangible signs of improved project management and margin stabilization in H2 results before considering a position.
• Pay close attention to any future guidance on the Lab Automation pipeline and the impact of the new, stricter contract models, as these will be leading indicators of whether the company can convert its high underlying demand into profitable growth.